MiR-138 Acts as a Tumor Suppressor by Targeting EZH2 and Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells
about
Downregulation of Enhancer of Zeste Homolog 2 (EZH2) is essential for the Induction of Autophagy and Apoptosis in Colorectal Cancer Cells.Regulation and role of post-translational modifications of enhancer of zeste homologue 2 in cancer developmentInhibition of MicroRNA-149-5p Induces Apoptosis of Acute Myeloid Leukemia Cell Line THP-1 by Targeting Fas Ligand (FASLG).MiR-138: A promising therapeutic target for cancer.MicroRNA-124 upregulation inhibits proliferation and invasion of osteosarcoma cells by targeting sphingosine kinase 1.MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells.Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.TUG1 promotes osteosarcoma tumorigenesis by upregulating EZH2 expression via miR-144-3p.MicroRNA-138 suppresses cell proliferation in laryngeal squamous cell carcinoma via inhibiting EZH2 and PI3K/AKT signaling.Noncoding RNA in drug resistant sarcoma.MicroRNA-137 acts as a tumor suppressor in osteosarcoma by targeting enhancer of zeste homolog 2.MicroRNA-138 directly targets TNFAIP8 and acts as a tumor suppressor in osteosarcoma.NOVA1 acts as an oncogene in osteosarcoma.MiR-101-3p Regulates the Viability of Lung Squamous Carcinoma Cells via Targeting EZH2.Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential.MicroRNA‑22 inhibits the proliferation and migration, and increases the cisplatin sensitivity, of osteosarcoma cells.Forkhead box N1 inhibits the progression of non-small cell lung cancer and serves as a tumor suppressor.MiR-92a Inhibits the Progress of Osteosarcoma Cells and Increases the Cisplatin Sensitivity by Targeting Notch1.High expression of EZH2 as a marker for the differential diagnosis of malignant and benign myogenic tumors
P2860
Q37373620-80F66AFF-8356-493C-B89E-32AF4F6D767CQ37545071-20E9E2E6-7AC2-4E2D-9336-3C7F490C01E2Q38724417-2BC01516-6B79-47BA-B68F-7690262AF24CQ38734800-FC542DC3-313F-406B-8110-98F973F94E52Q38741167-B78EBC10-510D-4F46-B9FC-224F77723C3AQ38750019-9B41379B-8A36-439A-91A6-E6606D1ED1C0Q38993869-9EC1D8F8-9BF7-44F9-9EF4-412C44B203FFQ41388665-8835393E-9F52-459D-B9FB-3BF9A8BA1BC0Q41672599-B3E192BD-F040-4290-9AC7-4962441B2FC4Q41924654-FC0B7B8E-8386-484E-A2FA-94ADAAAE4CF4Q42235455-91757E1A-995C-4333-9004-A0E819C8A032Q42376351-915B916E-AF84-478B-AFFA-71F880A4BEF4Q44715597-5AAD43D7-0898-444D-841A-F31396332CCBQ51267160-9A50B074-AEC6-46E9-849E-4683686760A1Q52349529-33A0A399-C41A-4962-8EF4-DF6A34823288Q52641330-6E84E8B1-387D-4432-AB21-26C46EEFAE46Q54090258-F594595C-B2CA-442D-B36C-291C8D93AC19Q55492687-948EAC58-928A-4C19-B5CF-1F48F6473143Q58771183-EC721F0B-B60F-4597-8CF0-4B4ACA753F0D
P2860
MiR-138 Acts as a Tumor Suppressor by Targeting EZH2 and Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
MiR-138 Acts as a Tumor Suppre ...... poptosis in Osteosarcoma Cells
@ast
MiR-138 Acts as a Tumor Suppre ...... poptosis in Osteosarcoma Cells
@en
MiR-138 Acts as a Tumor Suppre ...... poptosis in Osteosarcoma Cells
@nl
type
label
MiR-138 Acts as a Tumor Suppre ...... poptosis in Osteosarcoma Cells
@ast
MiR-138 Acts as a Tumor Suppre ...... poptosis in Osteosarcoma Cells
@en
MiR-138 Acts as a Tumor Suppre ...... poptosis in Osteosarcoma Cells
@nl
prefLabel
MiR-138 Acts as a Tumor Suppre ...... poptosis in Osteosarcoma Cells
@ast
MiR-138 Acts as a Tumor Suppre ...... poptosis in Osteosarcoma Cells
@en
MiR-138 Acts as a Tumor Suppre ...... poptosis in Osteosarcoma Cells
@nl
P2093
P2860
P3181
P1433
P1476
MiR-138 Acts as a Tumor Suppre ...... poptosis in Osteosarcoma Cells
@en
P2093
Jianqiang Wang
Jinshan Tang
Xiaoqing Zhou
Ziqiang Zhu
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0150026
P407
P577
2016-01-01T00:00:00Z